Selective T₃–T₄ sympathicotomy versus gray ramicotomy on outcome and quality of life in hyperhidrosis patients: a randomized clinical trial

Vicente Vanaclocha¹⁷, Ricardo Guijarro-Jorge²⁷, Nieves Saiz-Sapena³⁷, Manuel Granell-Gil³⁷, José María Ortiz-Criado⁴⁷, Juan Manuel Mascarós⁵⁷ & Leyre Vanaclocha⁶⁷

Compensatory hyperhidrosis is the leading cause of patients’ dissatisfaction after thoracic sympathectomy. The study aimed to reduce compensatory hyperhidrosis to increase patients’ satisfaction. A prospective randomized study on palmar hyperhidrosis, May 2016–September 2019. Twenty-one patients T₃–T₄ sympathicotomy and 21 T₃–T₄ gray ramicotomy. Data prospectively collected. Analysis at study’s end. Focus on the sweating, temperature, quality of life baseline and postoperatively, compensatory hyperhidrosis, hand dryness, patients’ satisfaction, and if they would undergo the procedure again and recommend it. No baseline differences between groups. Hyperhidrosis was controlled postoperatively in all patients. No mortality, serious complications, or recurrences. Sympathicotomy worse postoperative quality of life (49.05 (SD: 15.66, IR: 35.50–63.00) versus ramicotomy 24.30 (SD: 6.02, IR: 19.75–27.25). After ramicotomy, some residual sweating on the face, hands, and axillae. Compensatory sweating worse with sympathicotomy. Satisfaction higher with ramicotomy. Better results with ramicotomy than sympathicotomy regarding hand dryness, how many times a day the patients had to shower or change clothes, intention to undergo the procedure again or recommend it to somebody else, and how bothersome compensatory hyperhidrosis was. T₃–T₄ gray ramicotomy had better results than T₃–T₄ sympathicotomy, with less compensatory sweating and higher patients’ satisfaction.

Hyperhidrosis is a sympathetic nervous system dysfunction in which there is sweating beyond physiological needs¹. It affects mainly the hands and axillae², making social interaction difficult³. Medical treatments are helpful⁴⁵, but thoracic sympathectomy (TS) is used in refractory cases⁶⁷. Although practiced since 1920⁸, continuous improvements over the years have led to a progressive reduction in aggressiveness, morbidity, and mortality of TS⁶⁷.

Just after the TS patients are pleased as they do not longer sweat in the areas where it was incredibly cumbersome (hands and axillae)⁹, but as time goes by, especially during the summer, they notice sweating in areas that did not sweat before or not to such an extent, such as the abdomen, torso, buttocks, and thighs¹⁰. This new sweating is known as compensatory hyperhidrosis (CH) and is the fundamental cause of long-term patients’
dissatisfaction\(^{11–13}\). Another problem, although patients do not complain so often about it\(^{14}\), is the over-dryness of the sympathetically denervated area (head/face, hands, and axillae)\(^{15–16}\).

Removal of the sympathetic chain is no longer advocated\(^ {17–19}\). Instead, this chain’s surgical section, known as sympathicotomy (SY), is commonplace at different levels\(^ {19–23}\). However, this leaves the axillae, hands, face, and head with no possibility of sweating and temperature regulation\(^ {22,23}\). It has to be kept in mind that this area, the upper part of the body, represents 40% of the area through which we control our temperature by heat dissipation through sweating\(^ {24}\).

Over time the extent of sympathetic chain surgical lesion has been decreased, attempting to reduce the incidence and severity of CH\(^ {25,26}\). Many agree that the number of sympathetic ganglia injured should include only T\(_3\) and T\(_4\)\(^ {18,27–29}\). Some have tried applying clips instead of irreversibly damaging the nervous tissue\(^ {30}\). In bothersome CH, these clips can be removed and wait to hope for improvement\(^ {31}\). Unfortunately, this is not always the case\(^ {32,33}\).

Attempting further refinement, surgeons lesioned only the white and gray rami communicantes (RC) without injuring the sympathetic chain itself\(^ {34}\). This surgical technique reduced CH severity, but its incidence remained unaltered\(^ {35}\). Some recent studies have tried to lesion only the gray rami communicantes, leaving the white rami communicantes and sympathetic chain intact\(^ {36–38}\). Both studies showed a further reduction in the incidence and severity of CH, but the number of treated levels seemed excessive (T\(_2–T_5\) for Akil et al.\(^ {36}\) and T\(_2–T_4\) for Covelliers et al.\(^ {37}\)).

We hypothesized that the selective lesion of the gray T\(_3\) and T\(_4\) rami communicantes would be enough to reduce CH incidence and severity. In addition, this selective sympathetic system lesion should improve the patients’ satisfaction and reduce excessive dry hands, gustatory sweating, and cardio-pulmonary disorders (feeling of lack of strength when trying to lift a weight).

**Patients and methods**

**Study population.** We obtained Ethical and Research Committees’ approval, and we performed all methods following the relevant guidelines and regulations following the Helsinki Declaration rules. Clinical registration number CEIm 24-02-2016 (Comité de Ética e Investigación), date of approval 24/02/2016, ClinicalTrials.gov Identifier: NCT04721483, date of registration 22/01/2021.

We conducted this study between May 2016 and September 2019, including forty-two patients distributed in a prospective randomized fashion between two groups (Supplementary figure S1). We calculated the sample size based on previous research and used a block randomization model. We took eight blocks of four and two blocks of five patients with a random distribution of two patients from each group. This project was blind (only the surgeons knew which group the patients belonged to). A team member collected the data, unaware of which specific surgical procedure had undergone each patient. The procedure was a classical T\(_3–T_4\) SY in twenty-one patients and a selective T\(_3–T_4\) gray RC lesion in the other twenty-one.

Dermatology referred the patients to us once all conservative treatments proved inefficient or the patient refused to continue with them. Unfortunately, seven patients declined to participate in this study.

Data were prospectively collected and analyzed at the end of the study. We focused on the surgical procedures’ duration, the length of the hospital stays, the amount and severity of complications, and the sweating and temperature before and after the surgical procedure. We likewise recorded the intraoperative temperature rise in the hands, the quality of life baseline and on follow-ups, as well as the CH. We also registered how many times patients had to shower or change clothes, hand dryness, hand moisturizer, and satisfaction with the results. In addition, we asked patients if they would undergo the same procedure again and recommend it to somebody else. Finally, we measured postoperative B.M.I. changes as they might impact outcomes\(^ {38}\).

All patients suffered from palmar, axillary, and plantar HH, but the main reason to seek surgical treatment was excessive palmar sweating.

We documented informed consent for each patient, where patients agreed to be allocated randomly to either group and attend follow-up appointments.

The minimum postoperative follow-up required for patients included in our study was 12 months.

A member not participating in the patients’ care collected the data.

**Inclusion criteria.** Age 18–60 years, palmar HH with or without axillary HH refractive to conservative treatments or reluctant to continue with them after six months and willing to undergo surgical treatment, Hyperhidrosis Disease Severity Score grade D\(^ {39}\).

**Exclusion criteria.** Previous thoracic pathology (lung infections, particularly pulmonary empyema, pneumothorax, hemothorax, rib fractures, neoplasms), heart failure, hypothyroidism, tuberculosis, bradycardia (40 pulsations/min), alcoholism, drug addiction, BMI > 30, pregnancy, generalized HH or related to any health disorder, comorbidities or medication intake that induce excessive sweating. We excluded patients with primary facial or plantar HH and those not complying with follow-ups.

**Baseline patients’ evaluation.** On their first consultation and at each follow-up appointment, patients fulfilled the quality of life questionnaire developed by Amir et al.\(^ {40}\) (Supplementary table S1). We asked patients not to use any ointment, cream on the skin, or do physical exercise before the evaluation. We recorded baseline sweating and skin temperature at the forehead, palms of hands, axillae, abdomen, thighs, and soles of feet. We placed patients in a closed room for 15 min at 25 °C and 60% humidity (SAIVOD, Shenzhen, China). We collected the sweat with an absorbent pad (DELIPLUS, Mercadona, Paterna, Valencia, Spain). We recorded each absorbent pad’s using a precision scale (GRAM FH 6000, Gram Precision S.L., l’Hospital de Llobregat, Barce-
Surgical procedure. Step 1. Patients underwent general anaesthesia with double-lumen endotracheal intubation (VYGON US, Montgomeryville, PA, USA). We inserted intradermal electrodes (MTS-400010, Level Myocardial Temperature Sensor, Smiths Medical ASD, Inc., Rockland, MA 02370 USA) in the thenar eminences. We placed patients in the semi-Fowler position with the arms abducted 45°.

We used a thoracoscope (Storz code 26034AV, Karl Storz Endoscope, Tüttlingen, Germany).

The camera we used was a TELECAM (Storz code 2021030, Karl Storz Endoscope, Tüttlingen, Germany). The TV monitor was a TELE PACK X LED (Karl Storz Endoscope, Tüttlingen, Germany). The optic employed had a bayonet shape, allowing the introduction of pincers, scissors, or a right-angle hook.

After lung collapse, we inserted two portals (THORACIC TROCAR 13 mm/7 cm, Unimax Medical Systems Inc., Hsin Tien, Taipei, Taiwan) at the third intercostal space midaxillary line.

On inserting the portals, the lungs collapsed. Only four patients (4 lungs) required 600–1000 ml of CO₂ gas insufflation to induce a pneumothorax.

We inspected the pleural cavity and sectioned any adhesions. We undertook a thorough examination to identify the ganglia and the gray RC at T₃ and T₄.

Step 2. At this moment, patients underwent a T₃ and T₄ SY (Step 3A) or a T₃ and T₄ gray ramicotomy (RY) (Step 3B).

We opened the parietal pleural 5 mm lateral to the sympathetic chain with an "L" tip monopolar electrode (Storz code 26778 F, Karl Storz Endoscope, Tüttlingen, Germany). Then, we dissected with endoscopic Metzenbaum scissors (34421 MS, Karl Storz Endoscope, Tüttlingen, Germany).

Step 3A: T₃ and T₄ sympatheticotomy. The sympathetic chains were interrupted at the third and fourth ribs with harmonic scissors (Harmonic Scissors ACE™ + Laparoscopic Shears HARH45, Ethicon Endo-Surgery, Cincinnati, OH, 45242–2839 USA). We used a harmonic scalpel instead of a monopolar scalpel to achieve a more selective lesion. Bleeding from any nearby vessels was controlled by clip application.

Step 3B: T₃ and T₄ selective gray ramicotomy. We only dissected free the T3 and T4 gray RC in this group, leaving the white RC, sympathetic chain, and ganglia untouched.

Once isolated, we sectioned the gray RC with harmonic scissors. We coagulated the pleura over the third and fourth ribs over 2 cm to ensure that we had sectioned all gray RC or Kuntz's nerves. The sympathetic chain was not dissected or elevated from the ribs to avoid damaging it, its ganglia, or the white RC.

Intraoperative outcome measures. Intraoperative ablation of the sympathetic system was suspected with the change in the pulse oximeter amplitude, indicating increased hand blood circulation reported by other researchers. We used a rise of 0.8 °C or higher to confirm the sympathetic system interruption intraoperatively, as published by other researchers.

Step 4: Closure. Once we completed the elective sympathetic nervous system lesion, we inspected the pleural cavity. On inserting a 14-French tube, we applied suction to the pleural cavity to remove all the air and CO₂, the lung re-expanded, and the anaesthetist used a Valsalva equivalent manoeuvre. Next, we removed the 14-French thoracic tube under positive end-expiratory pressure. A tight subcutaneous purse-string suture ensured air-tight sealing, and we closed the skin with an intracutaneous suture.

Postoperative hospital stay and care. Postoperatively patients used an incentive spirometer to enhance pulmonary re-expansion. Discharge from the hospital took usually place the day after surgery. We advised patients to return to everyday daily life within 3–7 days and avoid intense physical activity for 15 days.

Follow-up. One month postoperatively, we measured the sweating and temperature in the same manner and anatomical areas again. In addition, we requested patients complete the same quality of life scale form as fulfilled preoperatively plus a specific postoperative form developed by us (Table 1). These same studies and questionnaires were re-recorded in all follow-ups, at one year postoperatively and in July past the first postoperative year. Afterwards, patients had yearly follow-ups.

Outcome measures. We evaluated the incidence of pleural adhesions found in the surgical procedure, the time to undertake the operation on each side, the postoperative complications, the hospital stay, and the recurrence rate.

At each follow-up, we recorded sweating and skin temperature at the forehead, palms of hands, axillae, abdomen, thighs, and soles of feet under the same temperature and humidity conditions as in baseline.

Patients graded CH as 1-absent, 2-mild, 3-embarrassing or moderate, 4-disabling or severe, and 5-extreme. Grade 2 means minor and intermittent sweating in elevated temperatures or humid environments or during physical activity. Meanwhile, grade 3 represents intense sweating in raised temperatures or high-humidity
POST-operative situation:

|                                      | YES | NO |
|--------------------------------------|-----|----|
| Excessively dry hands                |     |    |
| Do you need hand cream (more than before the operation) | YES | NO |
| I notice a difference in the taste of food | YES | NO |

Looking backwards:

|                                      | 1 very unhappy | 2 unhappy | 3 dissatisfied | 4 not completely happy | 5 very happy |
|--------------------------------------|----------------|-----------|---------------|------------------------|--------------|
| I am satisfied with the result       |                |           |               |                        |              |
| I would undergo sympathicotomy/radicotomy again | 1 I regret the operation | 2 better not | 3 perhaps not | 4 yes but with some concerns | 5 yes absolutely |
| I would recommend the procedure to another person | 1 not at all | 2 better not | 3 perhaps not | 4 yes but with some concerns | 5 yes absolutely |
| The reason for NOT recommending to undergo sympathicotomy/radicotomy is | Compensatory hyperhidrosis | Residual pain | Dry hands | Loss of strength in arms | Eyelid droop |

If you are unhappy with the outcome of the sympathicotomy/radicotomy, the reason for your dissatisfaction is:

| Compensatory hyperhidrosis | YES | NO |
|----------------------------|-----|----|
| In what area of your body disturbs you most from the compensatory hyperhidrosis? | Face | Arms | Axillae | Chest | Abdomen | Back | Groins | Thighs |
| Permanent post-operative pain | YES | NO | Where? Could you describe it? |
| Eyelid fall (Hörner syndrome) | YES | YES | Have you required any surgical treatment? Please describe it |
| Loss of strength in upper limbs | YES | NO | Describe in what activity |
| Heart rhythm disturbances | YES | NO | Describe when and how |

In the case of presenting compensatory hyperhidrosis, how would you describe it?

|                                      | 1 | 2 | 3 | 4 | 5 |
|--------------------------------------|---|---|---|---|---|
| In the winter | YES/NO | | | | |
| In the spring | YES/NO | | | | |
| In the summer | YES/NO | | | | |
| In the autumn | YES/NO | | | | |

Table 1. (continued)
The anatomical area affected by compensatory hyperhidrosis and its severity is?

|        | 1 | 2 | 2 | 4 | 5 |
|--------|---|---|---|---|---|
| Face   |   |   |   |   |   |
| Hands  |   |   |   |   |   |
| Arms   |   |   |   |   |   |
| Chest  |   |   |   |   |   |
| Abdomen|   |   |   |   |   |
| Back   |   |   |   |   |   |
| Buttocks|   |   |   |   |   |
| Groins |   |   |   |   |   |
| Thighs |   |   |   |   |   |
| Gustative |   |   |   |   |   |

What triggers compensatory hyperhidrosis?

|                  | 1 | 2 | 3 | 4 | 5 |
|------------------|---|---|---|---|---|
| The heat         |   |   |   |   |   |
| The humidity     |   |   |   |   |   |
| Closed environments |   |   |   |   |   |
| Physical exercise|   |   |   |   |   |
| Emotional stress |   |   |   |   |   |
| Public speaking  |   |   |   |   |   |

How do you adapt to compensatory hyperhidrosis?

|                                                                 | YES | NO |
|-----------------------------------------------------------------|-----|----|
| Do you need to do anything special?                             |     |    |
| Do you take a shower more than once a day?                      |     |    |
| How many times do you have to take a shower in a day?           | 1   |    |
| 2                                                               |     |    |
| 3 or more (describe)                                            |     |    |
| Do you have to change one or more clothes once a day?           |     |    |
| How many times a day do you have to change your clothes?        | 1   |    |
| 2                                                               |     |    |
| 3 or more (describe)                                            |     |    |
| Do you need to take medication to control the compensatory hyperhidrosis? |     |    |
| Under what circumstances do you need to take medication to control the compensatory hyperhidrosis? | Occasional circumstances: describe them | Every day or regularly |
| What medication do you need to take to control the compensatory? Describe the drug, the dose and the times you need to take it daily |     |    |

Pain at chest wall / upper limbs

|                          |     |
|--------------------------|-----|
| I feel no pain           |     |
| It hurts, but I endure without medication                     |     |
I need to take medication to control the pain occasionally

I have to take medication to control the pain regularly

What medication do you need to take to control the pain, the dose and how many times a day?

Any additional comment you wish to make

Patient’s signature:

Table 1. Postoperative quality of life scale form. A lower score indicates a better quality of life.

| Environments or during intensive physical activities. Lastly, grade 4 is applied when abundant sweating occurs even in mild climates or environments with normal humidity levels or without physical activity, bothering the patient and causing their clothes to get wet so that they need to change them during the day. The patients graded dryness following the scale proposed by Lee et al. 2004: as 1-excessive dry hand, 2-dry hands, and 3-the same hand sweating as before the operation. Overall patient satisfaction was measured using a five-point scale with the following grading: very unhappy, unhappy, dissatisfied, not completely happy, or very happy. Quality of Life Questionnaire, values over 84 indicated a pretty poor quality of life, low from 69 to 84, proper from 36 to 51, and excellent from 20 to 35.

Primary and secondary endpoints. The primary endpoint was the prospective objective evaluation of CH’s incidence and severity in treating primary hyperhidrosis patients with T3–T4 SY versus T3–T4 RC in age- and sex-matched controls. In addition, we will present the results as the rate of symptom resolution and the degree of postoperative patient satisfaction. The secondary endpoints evaluated the incidence of dry hands, gustatory sweating, complication rate, hospital stay, and recurrences of T3–T4 SY versus T3–T4 RC.

Ethical approval. Ethical and Research Committees approval obtained from CEIm Hospital General Universitario de Valencia, 26th of February 2016, ClinicalTrials.gov Identifier: NCT04721483.
Statistical analysis. We performed it using the statistical software R v3.4.0. (Hornik (2020), “The R FAQ”, https://cran.r-project.org/doc/FAQ/R-FAQ.html#citing-this-document) on an Excel database (Excel, Microsoft Corporation, Redmond, WA, USA).

The objective was to compare the decrease in the quality of life questionnaire pre and postoperatively for each group.

Pre-study. When comparing the means of two independent groups, we assumed a two-tailed problem, with an alpha (Type I Error) of 0.005, Power of 0.95 (Type II Error). To obtain the effect size, we assumed that the patient in the RY group suffered a decrease of sixty points on average, and the patients in the SY group suffered a reduction of fifty points on average. We also assumed that both had a similar standard deviation of around nine points so that the effect size was 1.11. With these assumptions, each of the arms needed at least nineteen patients. Adding a 10% patient power loss, at least twenty-one patients in each arm were required.

We conducted the sample size calculation using the G*Power statistical software.

Post-study. We calculated the mean, standard deviation (SD), median, and interquartile range (IR) for the continuous variables. We compared the groups’ continuous variables with the t-test when values were parametric and with the Mann–Whitney U test when they were not. We calculated the percentages for each group and compared them with the chi-square test for the discrete variables. The level of statistical significance used was 5% (p value < 0.05).

Results
We excluded one patient from each group because they did not attend the postoperative follow-ups.

Table 2 shows the patient’s demographic data and baseline quality of life according to the group. Preoperatively there were no statistically significant differences between groups based on age, gender, comorbidities,
smoking, BMI, quality of life, sweating (Fig. 1, Supplementary table S4), and temperature (Fig. 2, Supplementary table S5).

Only one patient belonging to the SY group had pleural adhesions that we lysed uneventfully. No surgery required conversion to an open thoracotomy. We could control all intraoperative haemorrhages endoscopically. Intraoperatively thenar eminence temperature rose more in the SY than in the RY (right hand 0.92 (SD: 0.51), IR: 0.50–1.20 vs. 0.51 (SD: 0.19), IR: 0.48–0.70, left hand 0.88 (SD: 0.41), IR: 0.50–1.02 vs. 0.62 (SD: 0.21, IR: 0.48–0.80)) (Supplementary table S6). The postoperative stay was longer for the SY group (2.05, SD: 1.82 vs. 1.15, SD: 0.37) due to one case of hemothorax and another to pneumothorax requiring inserting a thoracic drain. The bleeding was controlled endoscopically during the surgical procedure, but a drain was inserted to ease blood removal postoperatively and shorten postoperative stay. We had no mortality and no Horner’s syndromes. The surgical complications only lengthened the hospital stay.

The mean follow-up is 33 months (Range: 22–44).

The following data were recorded in July, coinciding with the warmest temperatures and maximum humidity. Analyzing the postoperative quality of life scale, patients undergoing SY reported worse results (49.05 (SD: 15.66), IR: 35.50–63.00 vs. 24.30 (SD: 6.02), IR: 19.75–27.25) (Table 3). A higher figure in the quality of life scale means a smaller improvement postoperatively. Patients in the SY group sweated less in the hands, axillae, and forehead but much more in the abdomen, thighs, and feet (Fig. 3, Supplementary table S7). SY patients had a more significant postoperative temperature rise in the forehead, with a colder temperature in the abdomen, thighs, and soles of feet than those in the RY group (Fig. 4, Supplementary table S8).

We could not attribute the postoperative differences observed in sweating, temperature, and CH to BMI changes as we saw no statistically significant differences between the groups (SY 24.41, SD: 3.99 vs. RY 23.41, SD: 2.14) (Table 3).
Patients completed a postoperative form asking about the CH (Table 1), where they experienced it, where it bothered most, its severity, and the adopted adaptive measures. Again, results were better for the RY than for the SY group (Table 3).

The preoperative and postoperative July past one-year follow-up data was compared (Supplementary table S2). Although all patients improved, this improvement was more significant in the RY group. In addition,
the temperature changes were milder for the RY group than the SY patients (Supplementary table S3). These temperature changes attest to a milder sympathetic lesion for the first than for the second group.

Patients have reported no recurrences at this time, with a maximum follow-up of 4 years.

**Discussion**

Ever since the introduction of TS in the treatment of palmar and axillary HH, there has been a continuous quest to find a way to reduce its most unpleasant side effect: CH\(^2\). Following the idea of minimizing the surgically induced damage to the sympathetic chain Wittmoser\(^3\) introduced in 1992 RY’s technique. It entailed the selective lesion of the rami communicantes, both white and gray, from \(T_2\) to \(T_4\) ± \(T_5\). The procedure ended with the sympathetic chain’s elevation from its bed to ascertain that no rami communicantes, either gray or white, were left intact. This surgical technique was not as selective as expected because it damaged the sympathetic input for the lungs and heart and the head and face\(^4\). Wittmoser described this surgical technique but did not undertake

[Figure 3. Postoperative sweating in different anatomical areas. Please notice some residual sweating in the partially sympathetically denervated areas in the RY, while there is almost none in the sympathicotomy. In addition, there is an increase in sweating in the abdomen, thighs, and feet in this last group that does not happen in the first group.]

[Figure 4. Postoperative temperature of the different anatomical areas. We see a more significant drop in the abdomen, thighs, and feet in the sympathicotomy group, attesting that they suffer from a more substantial CH. Also, notice that the temperature rises more in the forehead, hands, and axillae, showing that the sympathetic denervation is more prominent in the sympathicotomy group.]
any clinical trial and never published any results. Gossot in 1997 reported his results in 62 patients in whom he lesioned the T2 to T4 ± T5 gray and the white rami communicantes with the elevation of the sympathetic chain. He compared this technique with the SY of the same ganglia in fifty-four patients. He found that CH’s incidence was the same in both groups, but the severity was less in the RY than in the SY group. However, the recurrence rate was more prominent in the first than in the second group (5% RY vs. 0% SY). This increase in the recurrence rate was a deterrent for spreading this surgical technique of grey and white rami communicantes lesion. Nevertheless, this study showed that lesser sympathetic denervation meant that the hands’ palms could retain residual sweating. Other researchers have confirmed these results (Table 4).

In the following years, more studies compared the SY with the RY, confirming that RY has a lower incidence of CH, with less dry hands but with some recurrences14,18,26,53,55,56. The technique used to perform the RY kept being the section of both the gray and white rami communicantes with the sympathetic chain’s elevation. On further analysis of this group of publications, we realize that the number of levels treated is not uniform. Two of them include the rami communicantes of the T2 ganglion15,47. Nowadays, we know that lesioning this ganglion should be avoided as it correlates with a more severe CH14,18,26,53,55,56. In three other studies, only the rami communicantes of the T3 ganglion are sectioned48,50,51. These studies report the most significant recurrence rate (8.8% and 21.4%). In one study, researchers reported T2 and T3 gray and white rami communicantes lesions with the sympathetic chain’s elevation15. The researchers in this group say an incidence of CH of 23.07% and a recurrence rate of 15.38%. Lesion of T3 and T4 gray and white rami communicantes had an incidence of CH of 10.9% and no recurrence. In conclusion, the recommendation is to avoid T2 lesions and damage only T3 and T4.

In a step forward, Coveliers et al. lesioned only the T2–T4 gray rami communicantes not touching the sympathetic chain nor the white rami communicantes. The incidence of CH dropped to 7.2%, and they do not report any recurrence. Akil et al. reported the lesion of the T2–T3 gray rami communicantes with no CH and no recurrences. HH’s rate of control ranges from 96% to 100%. Both studies entail a more extensive lesion, including T2 and one of those studies, T3. There is an agreement in many previous reports to avoid lesioning T2 to reduce the incidence and severity of CH.

| Author          | Year | No. pts | SY/RY | Surgical technique | SY/RY | Success rate (%) | % CH | % GS | % Dry hands | PHH | % RH | Follow-up post-op | Satisfaction rate (%) |
|-----------------|------|---------|-------|-------------------|-------|------------------|------|------|-------------|-----|------|------------------|-----------------------|
| Akil et al 2018 | 0/51 | –/T2–T5 gray lesion | Sch NOT lifted | –/100 | –/0 | ND | ND | ND | ND | 4 mo, phone or email 12 ± 2.5 months | –/100 |
| Coveliers et al 2013 | 0/55 | –/T2–T4 gray lesion | Sch NOT lifted | –/96 | –/7.2 | ND | ND | ND | ND | 24 mo (3–36 months) | ND |
| Hwang 2013 46/43 | T2 SY/T2–T4 gray + white lesion | Sch lifted | 97.8/83.7 | 37.2/10.9 severe in 14/8.7 | ND | 82.6/25.6 | 15.2/58.5 | ND | At 1 month + phone 1-year | 79.1/91.3 |
| Lee et al 2004 64/83 | T2 SY/T2–T4 gray + white lesion | Sch lifted | 93.8/69.9 | 43.3/15.5 | ND | 6.2/18.1 | 6.25/30.1 | 0/8.8 | Phone 9.7 ± 1.3 vs 6.6 ± 3.7 months | 78.1/68.6 |
| Kim et al 2004 22/22 | T2 clip/T2 gray + white lesion | Sch lifted | ND | 75.5/36.4 | 4.4/0 | 22.7/13.6 | 0/18.3 | ND | Phone 20.1 ± 7.7 vs 10.8 ± 2.0 mo | 77.3/63.6 |
| Lee et al 2003 40/68 | T2 clip/T2 gray + white lesion | Sch lifted | 90/67.6 | 94/67.4 | ND | ND | 8.9/23.5 | ND | Phone 6.6 ± 3.7 vs 28.2 ± 6.2 mo | 82.5/67.6 |
| Cho et al 2003 13/13 | T2 clip/T2 RY technique | ND | 92.9/54.5 | ND | SY only % 1.4 out of 4 | SY only % 2 out of 4 | 6.7/21.4 | ND | 5.5/6.5 out of 10 |
| Cheng et al 2001 34/13 | T2–T1, SY/T1–T3 gray + white lesion | Sch lifted | ND | 82/23.07 | ND | ND | 0/15.38 | Mean 9 mo | ND |
| Gossot et al 1997 54/62 | T2–T4 ± T5 SY/T2–T4 ± T5 gray + white lesion | Sch lifted | 100/100 | 50/21 | ND | ND | ND | 0/5 | Mean 11 mo | ND |
| Wittmoser et al 1992 | –/ | T2–T4 gray + white lesion | NA | NA | NA | NA | NA | NA | NA | NA |

Table 4. Summary of the studies on endoscopic thoracic RY over the years. Sympathicotomy (SY). Ramicotomy (RY). Sch (Sch) Compensatory sweating (CH). Gustatory sweating (GS). Persistent hand humidity (PHH). Recurrence hyperhidrosis (RH). Not described (ND). Phone (follow-up performed through a telephone questionnaire).
Table 4 summarizes the results of all the research groups involved over the years with RY. The first problem with analyzing all these research groups is that they report CH's incidence and severity based on the patients' subjective report. Some researchers report discrepancies between subjective perception and objective measurement of hyperhidrosis and CH. Moreover, different patients react differently to the same degree of residual or new sweating. The oldest method to measure sweat production, the Quinizarin sweat test, is inaccurate. Gravimetry is more objective but still far from ideal. It entails giving a pre-weighted tissue, cotton swab, or piece of filter paper to the patient and asking them to wipe the area under investigation for 1 min in a room with temperature 24–25°C and humidity 15–17%. Then, the investigator weighs the tissue, cotton swab, or piece of filter paper again, and the increase in weight gives the amount of sweat in milligrams. This technique of sweat measurement did not seem accurate enough for our study. The most objective method is the VapoMeter* closed-chamber device (Delfin Technologies Ltd, Kuopio, Finland). The problem is that it only analyzes a tiny skin area (about 2.5 cm in diameter) at a time. Our study measured sweat production in milligrams of water recovered from an absorbent pad and temperature changes measured in degrees Celsius.

The second drawback is that in all the studies, the researchers did the follow-up through telephone or email questionnaires, which could be insufficient for objective assessment of the percentage and severity of CH. For this reason, our study exclusively used face-to-face follow-ups in our out-patients Department.

In our study, all the SY patients and the RY groups got complete relief from the palmar HH. The T3–T4 gray rami communicantes RY has shown much better results than SY levels concerning CH, dry hands, and patient satisfaction. Although the surgical time is somewhat longer in RY than in the SY group, this extra time seems warranted to achieve better results. No mortalities or severe complications happened in any group, besides one case of pneumothorax and another of hemothorax. Hence the quality of the result must guide our decision when using one surgical technique or the other. The lesion of T2 and T5 gray rami communicantes, practised by other researchers, does not seem justified.

An additional advantage is that the gray rami communicantes RY leaves some residual sweating in the hands. Former studies involving gray and white rami communicantes lesions already reported this residual hand moisture. However, researchers make no comments on this particular issue in the only two reports involving only the gray rami communicantes lesion. In our study, the need for a hand cream to combat postoperative hand dryness is present in 45% of the SY group patients and none of the RY patients (Table 3). This need for hand cream shows that postoperatively the hands are less dry in the RY than in the SY group.

Limitations
Our study's limitations are the reduced number of patients in each group and the need to gather more long-term data, particularly on possible H.H. recurrences.

Strengths
It is a prospective randomized study. A third party recorded the data, and the follow-ups were done by attending patients face-to-face and not through telephone or email questionnaires.

Conclusions
Compared with T3–T4 SY, T3–T4 gray RY shows better results. In addition, patients suffer from less CH and manifest greater satisfaction. Therefore, a more extensive RY does not seem necessary.

Received: 10 December 2020; Accepted: 11 August 2021
Published online: 02 September 2021

References
1. Coon, E. A. & Cheshire, W. P. Sweating disorders. Contin. Minnep. Minn. 26(1), 116–137 (2020).
2. Baumgartner, F. J. & Toh, Y. Severe hyperhidrosis: Clinical features and current thoracosurgical surgical management. Ann. Thorac. Surg. 76(6), 1878–1883 (2003).
3. Kamudoni, P. et al. The impact of hyperhidrosis on patients’ daily life and quality of life: A qualitative investigation. Health Qual. Life Outcomes 15(1), 121 (2017).
4. Fujimoto, T. Pathophysiology and treatment of hyperhidrosis. Curr. Probl. Dermatol. 51, 86–93 (2016).
5. McConaghy, J. R. & Fosselman, D. Hyperhidrosis: Management options. Am. Fam. Phys. 97(11), 729–734 (2018).
6. Hashmonai, M. The history of sympathetic surgery. Thorac. Surg. Clin. 26(4), 383–388 (2016).
7. Drott, C. The history of cervicothoracic sympathectomy. Eur. J. Surg. Suppl. Acta Chir. Suppl. 572, 5–7 (1994).
8. Kotzareff, A. Resection partielle de trone sympathetique cervicale droit pur hyperhidrose unilaterale. Rev. Med. Suisse Romande 40, 111–113 (1920).
9. Hajjar, W. M. et al. The quality of life and satisfaction rate of patients with upper limb hyperhidrosis before and after bilateral endoscopic thoracic sympathectomy. Saudi J. Anaesth. 13(1), 16–22 (2019).
10. Ruan, G. J. et al. Compensatory hyperhidrosis and quality of life post sympathectomy for palmar hyperhidrosis. Am. Surg. 85(4), 438–440 (2019).
11. Chwajol, M. et al. Impact of compensatory hyperhidrosis on patient satisfaction after endoscopic thoracic sympathectomy. Neu roursurgery 64(3), 511–518 (2009) (discussion 518).
12. Horslen, L. C., Wilshire, C. L., Louie, B. E. & Vallières, E. Long-term impact of endoscopic thoracic sympathectomy for primary palmar hyperhidrosis. Ann. Thorac. Surg. 106(4), 1008–1012 (2018).
13. Walles, T., Somuncuoğlu, G., Steger, V., Veit, S. & Friedel, G. Long-term efficiency of endoscopic thoracic sympathectomy: Survey 10 years after surgery. Interact. Cardiovasc. Thorac. Surg. 8(1), 54–57 (2009).
14. Zhang, W., Yu, D., Wei, Y., Xu, J. & Zhang, X. A systematic review and meta-analysis of T2, T3 or T4, to evaluate the best denervation level for palmar hyperhidrosis. Sci. Rep. 7(1), 129 (2017).
15. Cheng, Y. J., Wu, H. H. & Kao, E. L. Video-assisted thoracoscopic sympathetic ramicotomy for hyperhidrosis—A way to reduce the complications. Ann. Chin. Genecol. 90(3), 172–174 (2001).

16. Wilson, M. J., Magee, T. R., Galland, R. B. & Dehn, T. C. B. Results of thoracoscopic sympathectomy for the treatment of axillary and palmar hyperhidrosis with respect to compensatory hyperhidrosis and dry hands. Surg. Endosc. 19(2), 254–256 (2005).

17. Aydemir, B., Imamoglu, O., Okay, T. & Celik, M. Sympathectomy versus sympathectomy in palmar hyperhidrosis comparing T3 ablation. Thorac. Cardiovasc. Surg. 63(8), 715–719 (2015).

18. Scognamiglio, F. et al. T2–T4 sympathectomy versus T3–T4 sympathectomy for palmar and axillary hyperhidrosis. Clin. Auton. Res. Off. J. Clin. Auton. Res. Soc. 21(2), 97–102 (2011).

19. Chen, J. et al. Endoscopic thoracic sympathectomy for primary palmar hyperhidrosis: A retrospective multicenter study in China. Surgery 166(6), 1092–1098 (2019).

20. Karamustafaoglu, Y. A., Kuzucuoglu, M., Yanik, F., Sagiroglu, G. & Yoruk, Y. 3-year follow-up after uniportal thoracoscopic sympathectomy for hyperhidrosis: Undesirable side effects. J. Laparoendosc. Adv. Surg. Tech. A 24(11), 782–785 (2014).

21. Mohabbi, H. A., Mehrvaz, S. & Manoochehry, S. Thoracoscopic sympathectomy vs sympathectomy in primary hyperhidrosis. Trauma Mon. 17(2), 291–295 (2012).

22. Cramer, M. N. & Jay, O. Compensatory hyperhidrosis following thoracic sympathectomy: A biophysical rationale. Am. J. Physiol. Regul. Integr. Comp. Physiol. 302(3), R352–R356 (2012).

23. Shih, C. J. & Lin, M. T. Thermoregulatory sweating in palmar hyperhidrosis before and after upper thoracic sympathectomy. J. Neurol. 50(1), 88–94 (1979).

24. Shelley, W. B. & Florence, R. Compensatory hyperhidrosis of sympathectomy. N. Engl. J. Med. 263, 1056–1058 (1960).

25. Du, X. et al. Compensatory hyperhidrosis after different surgeries at the same sympathetic levels: A meta-analysis. Ann. Transl. Med. 6(11), 203 (2018).

26. Cai, S.-W. et al. Compensatory sweating after restricting or lowering the level of sympathectomy: A systematic review and meta-analysis. Clin. Sao Paulo Braz. 70(3), 214–219 (2015).

27. Chen, S. et al. T3 versus T4 video-assisted thoracoscopic sympathectomy for palmar hyperhidrosis: A protocol for a systematic review and meta-analysis. Medicine (Baltimore) 98(42), e17272 (2019).

28. Schmidt, J., Bechara, F. G., Altmeier, P. & Žmirglí, H. Endoscopic thoracic sympathectomy for severe hyperhidrosis: Impact of restrictive denervation on compensatory sweating. Ann. Thorac. Cardiovasc. Surg. 8(1), 105–108 (2006).

29. Aoki, H., Sakai, T., Murata, H. & Sumikawa, K. Extent of sympathectomy affects postoperative compensatory sweating and satisfaction in patients with palmar hyperhidrosis. J. Anesth. 28(2), 210–213 (2014).

30. Hida, K., Sakai, T., Hayashi, M., Tamagawa, T. & Abe, Y. Sympathotomy for palmar hyperhidrosis: the cutting versus clamping methods. Clin. Auton. Res. Off. J. Clin. Auton. Res. Soc. 25(5), 271–276 (2015).

31. Fibla Alfiera, J. J., Molins López-Rodó, L., Hernández Ferrándiz, J. & Guirao, M. A. Effectiveness of bilateral clipping of the thoracic sympathetic chain for the treatment of severe palmar and/or axillary hyperhidrosis and facial flushing. Cirugia Espanola 97(4), 196–202 (2019).

32. Kara, M., Kose, S., Ozkan, B. & Sertçakacaklar, G. Does clip removal help for compensatory hyperhidrosis complicating thoracic sympathetic clipping? Clin. Auton. Res. Off. J. Clin. Auton. Res. Soc. 29(3), 355–359 (2019).

33. Hynes, C. F., Yamaguchi, S., Bond, C. D. & Marshall, M. Reversal of sympathetic interruption by removal of clips. Ann. Thorac. Surg. 99(3), 1020–1023 (2015).

34. Wittmoser, R. Thoracoscopic sympathectomy and vagotomy. In Operative Endoscopic Surgery (eds Cuschieri, A. et al.) 110–133 (Springer, 1992).

35. Gossot, D., Toledo, L., Fritsch, S. & Célérier, M. Thoracoscopic sympathectomy for upper limb hyperhidrosis: Looking for the right operation. Ann. Thorac. Surg. 64(4), 975–978 (1997).

36. Akil, A., Semik, M. & Fischer, S. Efficacy of miniminiportal video-assisted thoracoscopic selective sympathectomy (ramicotomy) for the treatment of severe palmar and axillary hyperhidrosis. Thorac. Cardiovasc. Surg. 67(5), 415–419 (2019).

37. Coveliers, H. et al. Robotic selective postganglionic thoracic sympathectomy for the treatment of hyperhidrosis. Ann. Thorac. Surg. 95(1), 269–274 (2013).

38. Dobosz, L., Cwalina, N. & Stefanik, T. Influence of body mass index on compensatory sweating in patients after thoracic sympathectomy due to palmar hyperhidrosis. Thorac. Cardiovasc. Surg. 65(6), 497–502 (2017).

39. Solish, N. et al. Canadian Hyperhidrosis Advisory Committee. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol. Surg. 33(8), 908–923, https://doi.org/10.1111/j.1524-4725.2007.33192.x (2007).

40. Amir, M., Arish, A., Weinstein, Y., Pfeffer, M. & Levy, Y. Impairment in quality of life among patients seeking surgery for hyperhidrosis (excessive sweating): Preliminary results. Isr. J. Psychiatry Relat. Sci. 37(1), 25–31 (2000).

41. Huyven, D. et al. Electric vs. harmonic scalpel in treatment of primary focal hyperhidrosis with thoracoscopic sympathectomy. Eur. J. Cardio-Thorac. Surg. Off. J. Eur. Assoc. Cardio-Thorac. Surg. 21(2), 223–228 (2001).

42. Fischel, R., Cooper, M. & Kramer, D. Microinvasive resectional sympathectomy using the harmonic scalpel. A more effective procedure with fewer side effects for treating essential hyperhidrosis of the hands, face or axillae. Clin. Auton. Res. Off. J. Clin. Auton. Res. Soc. 13 Suppl 1, 166–170 (2003).

43. Georgiou, G. P., Berman, M., Bobovnikov, V., Vidne, B. A. & Saute, M. Minimally invasive thoracoscopic sympathectomy for palmar hyperhidrosis via a transaxillary single-port approach. Interact. Cardiovasc. Thorac. Surg. 3(3), 437–441 (2004).

44. Sáiz-Sapena, N., Vanaclocha, V., Panta, F., Kadri, C. & Torres, W. Operative monitoring of hand and axillary temperature during endoscopic superior thoracic sympathectomy for the treatment of palmar hyperhidrosis. Eur. J. Surg. Acta Chir. 160(1), 65–69 (2000).

45. Chung, T. Y. et al. Intraoperative monitoring of skin temperature changes of hands before, during, and after endoscopic thoracic sympathectomy: Using infrared thermograph and thermometer for measurement. Arch. Phys. Med. Rehabil. 78(1), 85–88 (1997).

46. Liu, Y. et al. Sympathectomy for palmar hyperhidrosis: The association between intraoperative palm temperature change and the curative effect. Ann. Thorac. Cardiovasc. Surg. Off. J. Assoc. Thorac. Cardiovasc. Surg. Asia 21(4), 359–363 (2015).

47. Kim, D. H., Paik, H. C. & Lee, D. Y. Comparative analysis of T2 selective division of rami communicantes (ramicotomy) with T2 sympathetic clipping in the treatment of craniofacial hyperhidrosis. Eur. J. Cardio-Thorac. Surg. Off. J. Eur. Assoc. Cardio-Thorac. Surg. 26(2), 396–400 (2004).

48. Lee, D. Y., Kim, D. H. & Paik, H. C. Selective division of T3 rami communicantes (T3 ramicotomy) in the treatment of palmar hyperhidrosis. Ann. Thorac. Surg. 78(3), 1052–1055 (2004).

49. Guimarães, P. S. F. et al. Ramicotomy in association with endoscopic sympathetic blockade in the treatment of axillary hyperhidrosis. Surg. Laparosc. Endosc. Percutan. Tech. 23(2), 223–228 (2013).

50. Hwang, J. I., Kim, D. H., Hong, Y. I. & Lee, D. Y. A comparison between two types of limited sympathetic surgery for palmar hyperhidrosis. Surg. Today. 43(4), 397–402 (2013).
53. Wekoler, B., Blaine, G., Souza, Z. B. B. & Gavina, R. Transection of more than one sympathetic chain ganglion for hyperhidrosis increases the severity of compensatory hyperhidrosis and decreases patient satisfaction. J. Surg. Res. 156(1), 110–115 (2009).
54. Salim, E. F. & Ali, G. A. Impact of thoracoscopic T2 sympathectomy on patients with primary palmar and axillary hyperhidrosis. Ann. Thoracic Surg. 106(4), 1032–1037 (2018).
55. Yazbek, G. et al. Palmar hyperhidrosis—which is the best level of denervation using video-assisted thoracoscopic sympathectomy: T2 or T3 ganglion?. J. Vasc. Surg. 42(2), 281–285 (2005).
56. Dogru, M. V. et al. Is there any relationship between quality of life and the level of sympathectomy in primary palmar hyperhidrosis? Single-center experience. Gen. Thorac. Cardiovasc. Surg. 68, 273–279 (2019).
57. Stefaniak, T. et al. Is subjective hyperhidrosis assessment sufficient enough? Prevalence of hyperhidrosis among young Polish adults. J. Dermatol. 40(10), 819–823 (2013).
58. Dobosz, L., Stefaniak, T., Halman, J. & Piekarska, A. Differences in subjective and objective evaluation of hyperhidrosis Study among medical students. Postepy Dermatol. Alergol. 37(5), 700–704 (2020).
59. Wang, H.-Y., Zhu, Y.-J., Liu, J., Li, L.-W. & Liu, Y.-H. The relationship between preoperative psychological evaluation and compensatory sweating. J. Cardiothorac. Surg. 13(1), 42 (2018).
60. Qian, K. et al. Anxiety after Sympathectomy in patients with primary palmar hyperhidrosis may prolong the duration of compensatory hyperhidrosis. J. Cardiothorac. Surg. 13(1), 54 (2018).
61. Guttmann, L. The management of the quinizarin sweat test (Q.S.T.). Postgrad Med J. 23(262), 353–366 (1947).
62. Atkinson, J. L. D., Fode-Thomas, N. C., Fealey, R. D., Eisenach, J. H. & Goerss, S. J. Endoscopic transthoracic limited sympathectomy for palmar-plantar hyperhidrosis: outcomes and complications during a 10-year period. Mayo Clin. Proc. 86(8), 721–729 (2011).
63. Stefaniak, T. J. & Proczyk, M. Gravimetry in sweating assessment in primary hyperhidrosis and healthy individuals. Clin. Auton. Res. Off. J. Clin. Auton. Res. Soc. 23(4), 197–200 (2013).
64. Hund, M., Kinkel, I., Naumann, M. & Hamm, H. Definition of axillary hyperhidrosis by gravimetric assessment. Arch. Dermatol. 138(4), 539–541 (2002).
65. Heckmann, M., Ceballos-Baumann, A. O., Plewig, G. Hyperhidrosis Study Group. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N. Engl. J. Med. 344(7), 488–493. https://doi.org/10.1056/NEJM200102213440704 (2001).
66. Larson, D. L. Definitive diagnosis and management of axillary hyperhidrosis: The VapoMeter and suction-assisted arthroscopic shaving. Aesthet. Surg. J. 31(5), 552–559 (2011).
67. Miotto, A. et al. Comparative study of transepidermal water loss in patients with and without hyperhidrosis by closed-chamber measurer in an air-conditioned environment. Einstein Sao Paulo Braz. 16(4), eAO4312 (2018).

Acknowledgements
To the Department of Physiology, Faculty of Medicine, the University of Valencia, particularly to Rosa Maria Cibrian Ortiz de Anda and all outpatient clinic personnel for the Thoracic Surgery and Neurosurgery Departments and particularly to Vicenta Miraval and to Ana M. Moreno Garcia.

Author contributions
Conception and design: VV
Analysis and interpretation: VV, RG, NS, LV
Data collection: VV, RG, MG, JO
Drafting the article: VV, NS, LV
Critical revision of the article: VV, RG, NS
Final approval of the article: VV, RG, NS, LV

Contribution of authors

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-96972-7.
Correspondence and requests for materials should be addressed to V.V.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021